On August 19, the official website of the National Health Commission issued the "Notice on Issuing the Diagnosis and Treatment Plan for the New Coronavirus Pneumonia", which further improved the source and transmission routes, increasing the "infectiousness during the incubation

htmlOn August 19, the official website of the National Health Commission issued the "Notice on Issuing the Diagnosis and Treatment Plan for the New Coronavirus Pneumonia (Trial Eighth Edition), which further improved the source and transmission routes, increasing the "infectiousness during the incubation period, and strong infectiousness within 5 days after onset of the disease" and "contacting items contaminated by viruses can also cause infection." In terms of diagnostic criteria, the positive effect of the novel coronavirus-specific IgM antibody is used as one of the diagnostic criteria for suspected cases.

In terms of clinical characteristics, the clinical manifestations of MIS-C are added, "A very small number of children may have multisystem inflammation syndrome (MIS-C)," which introduces the clinical manifestations of MIS-C. Added the "negative coronavirus-specific IgM antibodies and IgG antibodies to have a lower positive rate within 1 week of the onset" and the situation that may lead to false positive , and under what circumstances can be diagnosed through antibody testing.

Picture/Visual China

In terms of antiviral treatment, the eighth edition of the plan pointed out that some antiviral drugs may have certain therapeutic effects through clinical observation studies, but no antiviral drugs proved effective by strict "randomized, double-blind, placebo-controlled studies". It is recommended to use drugs with potential antiviral effects early in the course of the disease, and focus on patients with high-risk factors and tendencies to be used.

lopinavir/ritonavir and ribavirin alone are not recommended, hydroxychloroquine or combined azithromycin is not recommended. α- interferon , ribavirin (recommended to be used in combination with interferon or lopinavir/ritonavir), chloroquine phosphate, and abidor can be continued to be tried, and further evaluate the efficacy and adverse reactions, contraindications, and interaction with other drugs in clinical applications. It is not recommended to use more than 3 antiviral drugs at the same time. In the eighth edition of

plan, discharge standards and precautions after discharge are also refined. For patients whose body temperature returns to normal for more than 3 days, respiratory symptoms improve significantly and lung imaging shows that acute exudative lesions are significantly improved, such as those who continue to be positive for more than 4 weeks, it is recommended that "after a comprehensive assessment of the patient's infectivity is carried out through antibody testing, virus culture isolation and other methods, we will determine whether to be discharged from the hospital."

text/Yangcheng Evening News All-Media Reporter Zhang Hua Correspondent Guangdong Weixin